Jad Chahoud1, Adele Semaan2, Yong Chen3, Ming Cao3, Alyssa G Rieber4, Peter Rady5, Stephen K Tyring5. 1. Department of Internal Medicine, The University of Texas Health Science Center, University of Texas Medical School at Houston, Houston. 2. Department of Management Policy and Community Health, The University of Texas School of Public Health, Houston. 3. Department of Biostatistics, The University of Texas School of Public Health, Houston. 4. Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston. 5. Department of Dermatology, The University of Texas Medical School at Houston, Houston.
Abstract
Importance: Existing epidemiological evidence remains controversial regarding the association between β-genus human papillomavirus (β-HPV) and cutaneous squamous cell carcinoma (cSCC) in immunocompetent individuals. Objective: We aimed to clarify this association and evaluate type-specific β-HPV involvement. Data Sources: We performed a systematic literature search of MEDLINE and EMBASE for studies in humans through June 18, 2014, with no restriction on publication date or language. The following search terms were used: "human papillomavirus" and "cutaneous squamous cell carcinoma or skin squamous cell carcinoma or cSCC or nonmelanoma skin neoplasms." Study Selection: Articles were independently assessed by 2 reviewers. We only included case-control or cohort studies, in immunocompetent individuals, that calculated the odds ratio (OR) for cSCC associated with overall and type-specific β-HPV. Data Extraction and Synthesis: We first assessed the heterogeneity among study-specific ORs using the Q statistic and I2 statistic. Then, we used the random-effects model to obtain the overall OR and its 95% CI for all studies as well as for each type of HPV. We also tested and corrected for publication bias by 3 funnel plot-based methods. The quality of each study was assessed with the Newcastle Ottawa Scale. Main Outcomes and Measures: Pooled ORs and 95% CIs for overall β-HPV and HPV types 5, 8, 15, 17, 20, 24, 36, and 38 association with skin biopsy proven cSCC. Results: Seventy-nine articles were assessed for eligibility; 14 studies met inclusion criteria for the meta-analysis and included 3112 adult immunocompetent study participants with cSCC and 6020 controls. For all detection methods, the overall association between β-HPV and cSCC was significant with an adjusted pooled OR (95% CI) of 1.42 (1.18-1.72). As for the type-specific analysis, types 5, 8, 15, 17, 20, 24, 36, and 38 showed a significant association with adjusted pooled ORs (95% CIs) of 1.4 (1.18-1.66), 1.39 (1.16-1.66), 1.25 (1.04-1.50), 1.34 (1.19-1.52), 1.38 (1.21-1.59), 1.26 (1.09-1.44), 1.23 (1.01-1.50), and 1.37 (1.13-1.67) respectively. Our subgroup analysis in studies using only serology for HPV detection showed a significant association between overall β-HPV and HPV subtypes 5, 8, 17, 20, 24, and 38 with an increased risk of cSCC development. Conclusions and Relevance: This study serves as added evidence supporting β-HPV as a risk factor for cSCC in healthy individuals. The subgroup analysis highlights this significant association for HPV 5, 8, 17, 20, and 38, which may help to direct future prevention efforts.
Importance: Existing epidemiological evidence remains controversial regarding the association between β-genus human papillomavirus (β-HPV) and cutaneous squamous cell carcinoma (cSCC) in immunocompetent individuals. Objective: We aimed to clarify this association and evaluate type-specific β-HPV involvement. Data Sources: We performed a systematic literature search of MEDLINE and EMBASE for studies in humans through June 18, 2014, with no restriction on publication date or language. The following search terms were used: "human papillomavirus" and "cutaneous squamous cell carcinoma or skin squamous cell carcinoma or cSCC or nonmelanoma skin neoplasms." Study Selection: Articles were independently assessed by 2 reviewers. We only included case-control or cohort studies, in immunocompetent individuals, that calculated the odds ratio (OR) for cSCC associated with overall and type-specific β-HPV. Data Extraction and Synthesis: We first assessed the heterogeneity among study-specific ORs using the Q statistic and I2 statistic. Then, we used the random-effects model to obtain the overall OR and its 95% CI for all studies as well as for each type of HPV. We also tested and corrected for publication bias by 3 funnel plot-based methods. The quality of each study was assessed with the Newcastle Ottawa Scale. Main Outcomes and Measures: Pooled ORs and 95% CIs for overall β-HPV and HPV types 5, 8, 15, 17, 20, 24, 36, and 38 association with skin biopsy proven cSCC. Results: Seventy-nine articles were assessed for eligibility; 14 studies met inclusion criteria for the meta-analysis and included 3112 adult immunocompetent study participants with cSCC and 6020 controls. For all detection methods, the overall association between β-HPV and cSCC was significant with an adjusted pooled OR (95% CI) of 1.42 (1.18-1.72). As for the type-specific analysis, types 5, 8, 15, 17, 20, 24, 36, and 38 showed a significant association with adjusted pooled ORs (95% CIs) of 1.4 (1.18-1.66), 1.39 (1.16-1.66), 1.25 (1.04-1.50), 1.34 (1.19-1.52), 1.38 (1.21-1.59), 1.26 (1.09-1.44), 1.23 (1.01-1.50), and 1.37 (1.13-1.67) respectively. Our subgroup analysis in studies using only serology for HPV detection showed a significant association between overall β-HPV and HPV subtypes 5, 8, 17, 20, 24, and 38 with an increased risk of cSCC development. Conclusions and Relevance: This study serves as added evidence supporting β-HPV as a risk factor for cSCC in healthy individuals. The subgroup analysis highlights this significant association for HPV 5, 8, 17, 20, and 38, which may help to direct future prevention efforts.
Authors: Anna J Nichols; Amber Heyna Allen; Shahjahan Shareef; Evangelos V Badiavas; Robert S Kirsner; Tim Ioannides Journal: JAMA Dermatol Date: 2017-06-01 Impact factor: 10.282
Authors: Rossybelle P Amorrortu; Neil A Fenske; Basil S Cherpelis; Laxmi Vijayan; Yayi Zhao; Juliana Balliu; Jane L Messina; Vernon K Sondak; Anna R Giuliano; Tim Waterboer; Michael Pawlita; Tarik Gheit; Massimo Tommasino; Dana E Rollison Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-19 Impact factor: 4.254
Authors: Dana E Rollison; Michael J Schell; Neil A Fenske; Basil Cherpelis; Jane L Messina; Anna R Giuliano; Pearlie K Epling-Burnette; Shalaka S Hampras; Rossybelle P Amorrortu; Juliana Balliu; Laxmi Vijayan; Syeda Mahrukh Hussnain Naqvi; Yayi Zhao; Kaustubh Parab; Sandrine McKay-Chopin; Tarik Gheit; Massimo Tommasino Journal: J Infect Dis Date: 2019-02-15 Impact factor: 5.226
Authors: Priyadharsini Nagarajan; Maryam M Asgari; Adele C Green; Samantha M Guhan; Sarah T Arron; Charlotte M Proby; Dana E Rollison; Catherine A Harwood; Amanda Ewart Toland Journal: Clin Cancer Res Date: 2018-12-06 Impact factor: 12.531
Authors: Anna J Nichols; Adrianna Gonzalez; Emily S Clark; Wasif N Khan; Alyx C Rosen; Wellington Guzman; Harold Rabinovitz; Evangelos V Badiavas; Robert S Kirsner; Tim Ioannides Journal: JAMA Dermatol Date: 2018-08-01 Impact factor: 10.282
Authors: Flora Yan; Brittny N Tillman; Rajiv I Nijhawan; Divya Srivastava; David J Sher; Vladimir Avkshtol; Jade Homsi; Justin A Bishop; Erin M Wynings; Rebecca Lee; Larry L Myers; Andrew T Day Journal: Ann Surg Oncol Date: 2021-06-30 Impact factor: 5.344